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CYP2D6 function moderates the pharmacokinetics and
pharmacodynamics of 3,4-methylene-dioxymethamphetamine
in a controlled study in healthy individuals
Yasmin Schmida, Patrick Vizelia, Cédric M. Hyseka, Katharina Prestinb,
Henriette E. Meyer zu Schwabedissenb and Matthias E. Liechtia
The role of genetic polymorphisms in cytochrome (CYP)
2D6 involved in the metabolism of 3,4-methylene-
dioxymethamphetamine (MDMA, ecstasy) is unclear.
Effects of genetic variants in CYP2D6 on the
pharmacokinetics and pharmacodynamic effects of MDMA
were characterized in 139 healthy individuals (70 men, 69
women) in a pooled analysis of eight double-blind, placebo-
controlled crossover studies. In CYP2D6 poor metabolizers,
the maximum concentrations (Cmax) of MDMA and its active
metabolite 3,4-methylene-dioxyamphetamine were + 15
and + 50% higher, respectively, compared with extensive
metabolizers and the Cmax of the inactive metabolite
4-hydroxy-3-methoxymethamphetamine was 50–70%
lower. Blood pressure and subjective drug effects increased
more rapidly after MDMA administration in poor
metabolizers than in extensive metabolizers. In conclusion,
the disposition of MDMA and its effects in humans are
altered by polymorphic CYP2D6 activity, but the effects are
small because of the autoinhibition of CYP2D6.
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Interindividual differences in the clinical toxicity of
3,4-methylene-dioxymethamphetamine (MDMA) may
result from alterations in drug-metabolizing enzymes,
such as cytochrome P450 monooxygenases (CYPs), that
are involved in the metabolism of MDMA [1,2] shown in
Supplementary Fig. S1, Supplemental digital content 1,
http://links.lww.com/FPC/B41.
Only limited controlled data are available on the phar-
macogenetics/toxicogenetics of MDMA [2]. The aim of
the present study was to investigate the role of CYP2D6
in the PK of MDMA in a prospectively designed pooled
analysis of eight double-blind, placebo-controlled, cross-
over studies in a total of 139 healthy individuals (methods
shown in Supplemental digital content 1, http://links.lww.
com/FPC/B41). This is the first study with a meaningful
sample size and the inclusion of several individuals with
relevantly impaired function. We also performed both
genotyping and phenotyping and used genetic activity
scores [3] for CYP2D6 activity classification.
We found that CYP2D6 activity significantly altered
plasma MDMA levels up to 3 h after drug administration
(i.e. during drug absorption/distribution), but not beyond
3 h (i.e. during drug elimination; Supplementary Table
S1, Supplemental digital content 1, http://links.lww.com/
FPC/B41, Fig. 1a and Supplementary Fig. S2c,
Supplemental digital content 1, http://links.lww.com/FPC/
B41). A significant main effect of the CYP2D6 genotype
on the Cmax of MDMA was found (F2,136= 4.19, P= 0.02),
with higher Cmax values in CYP2D6 poor metabolizers
(PMs) compared with extensive metabolizers (EMs;
P= 0.049; Supplementary Fig. S1a, Supplemental digital
content 1, http://links.lww.com/FPC/B41). The CYP2D6
activity score similarly altered the Cmax of MDMA
(Supplementary Table S1 and Supplementary Fig. S2b,
Supplemental digital content 1, http://links.lww.com/FPC/
B41). MDMA area under the concentration–time curve
up to 6 h (AUC6) values also varied across CYP2D6
genotype groups (F2,136= 5.25, P< 0.01), with PMs
showing higher AUC6 values compared with EMs
(P< 0.01; Supplementary Fig. S2d, Supplemental digital
content 1, http://links.lww.com/FPC/B41). MDMA AUC6
values also differed between genotype-based CYP2D6
activity groups (Supplementary Table S1 and
Supplementary Fig. S2e, Supplemental digital content 1,
http://links.lww.com/FPC/B41). The CYP 2D6 genotype
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altered the concentration–time curve of the minor active
metabolite 3,4-methylene-dioxyamphetamine (MDA)
(Fig. 1b). The Cmax and AUC6 of MDA varied across
genotypes (F2,136= 8.82, P< 0.01, and F2,136= 9.09,
P< 0.001, respectively), which were higher in PMs
compared with intermediate metabolizers (IMs;
P< 0.001) and EMs (P< 0.001; Supplementary Fig. S3a
and d, Supplemental Digital Content 1, http://links.lww.
com/FPC/B41). The Cmax and AUC6 of MDA were also
higher in individuals with a CYP2D6 activity score of 0
compared with all of the other CYP2D6 activity groups
(Supplementary Table S1 and Supplementary Fig. S2b,
c, e, Supplemental digital content 1, http://links.lww.com/
FPC/B41). The CYP2D6 genotype influenced the
concentration–time curve of the inactive metabolite
4-hydroxy-3-methoxymethamphetamine (HMMA; Fig. 1c).
The CYP2D6 genotype altered the Cmax and AUC6 of
HMMA (F2,73= 3.50, P= 0.03 and 5.22, P< 0.01;
Supplementary Table S1 and Supplementary Fig. S4a
and d, Supplemental digital content 1, http://links.
lww.com/FPC/B41). Cmax and AUC6 of HMMA were
higher in individuals with high CYP2D6 activity (activity
score of 2) compared with individuals with low activity
(activity score of 0.5; Supplementary Table S1 and
Supplementary Fig. S4b, c, e, Supplemental digital
content 1, http://links.lww.com/FPC/B41). The CYP2D6
genotype altered the unconjugated HMMA concentra-
tions similar to those of HMMA (Supplementary Table
S2 and Supplementary Fig. S5, Supplemental digital
content 1, http://links.lww.com/FPC/B41). The CYP2D6
Fig. 1
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CYP2D6 phenotypes predicted by genotyping altered the pharmacokinetics of MDMA (a), MDA (b), HMMA (c), and the MDMA/HMMA ratio (d).
Lower CYP2D6 function as in PMs resulted in higher MDMA (a) and MDA (b) plasma levels, lower HMMA plasma levels (c), and higher MDMA/
HMMA plasma concentration ratios (d) compared with higher CYP2D6 function as in EMs. The data are expressed as the mean ±SEM in seven PMs,
19 IMs, and 113 EMs for MDMA and MDA. MDMA was administered at t=0 h. *P<0.05, **P<0.01, ***P<0.001 for PMs compared with EMs and
+P<0.05 for EMs compared with IMs at the corresponding time. CYP2D6, cytochrome 2D6; EMs, extensive metabolizers; HMMA, 4-hydroxy-
3-methoxymethamphetamine; IM, intermediate metabolizers; MDA, 3,4-methylene-dioxyamphetamine; MDMA, 3,4-methylene-dioxymethamphetamine;
PMs, poor metabolizers.
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genotype altered the MDMA/HMMA Cmax and AUC6
ratios (F2,73= 10.98 and 10.08, both P< 0.001; Fig. 1d).
CYP2D6 PMs had higher MDMA/HMMA Cmax and
AUC6 ratios compared with IMs (P< 0.01 and P< 0.05)
and EMs (both P< 0.001; Fig. 1d, and Supplementary
Fig. S6a and d, Supplemental digital content 1, http://
links.lww.com/FPC/B41). Individuals with a CYP2D6
activity score of 2 had lower MDMA/HMMA Cmax and
AUC6 ratios compared with individuals with activity
scores of 0, 0.5, and 1 (Supplementary Table S1 and
Supplementary Fig. S6b, c, e, Supplemental digital
content 1, http://links.lww.com/FPC/B41). The effects of
CYP2D6 on the biotransformation of MDMA to HMMA
over time are also evident in the hysteresis plots in
Supplementary Fig. S8, Supplemental digital content 1,
http://links.lww.com/FPC/B41. A correlation was found
between the AUC6 values of MDMA and MDA
(Rs= 0.18, P< 0.05, N= 139), indicating that higher
MDMA levels resulted in higher MDA levels. In con-
trast, higher AUC6 values of MDMA were negatively
correlated with those of HMMA (Rs=− 0.33, P< 0.01,
N= 76) or unconjugated HMMA (Rs=− 0.39, P< 0.001,
N= 124), consistent with the impaired conversion of
MDMA into HMMA.
CYP2D6 activity influenced both the cardiovascular and
the psychotropic responses to MDMA. Both the MDMA-
induced blood pressure response and subjective drug
effects increased more rapidly in genotype-based
CYP2D6 PMs compared with IMs and EMs (Fig. 2),
reflected by group differences early in time after MDMA
administration, whereas maximal effects did not differ.
Elevations in systolic blood pressure were greater in PMs
compared with IMs (P= 0.02) and EMs (P= 0.01) at 0.6 h
(F2,135= 3.50, P= 0.03) and also tended to be greater at
1 h (F2,135= 2.49, P= 0.09) after drug administration.
Subjective ‘any drug effect’ ratings were higher in PMs
compared with both IMs and EMs at 0.6 h (P< 0.05).
‘Drug liking’ ratings were higher in PMs compared with
both IMs and EMs at 0.6 h (P< 0.001) and 1 h (P< 0.01)
and tended to be higher at 1.5 h. No effects of the
CYP2D6 genotype were found on heart rate or body
temperature. The MDMA/HMMA ratio at 0.6 h, which
inversely reflects CYP2D6 activity, was associated with
the MDMA-induced elevations in systolic blood pressure
(Rs= 0.41, P< 0.001, N= 76), any drug effect (Rs= 0.42,
P< 0.001), and drug liking (Rs= 0.40, P< 0.001) at 0.6 h.
The association remained significant for systolic blood
pressure up to 1.5 h and for any drug effect and drug
liking up to 4 and 6 h, respectively.
As expected, the CYP2D6 phenotype was associated
with the CYP2D6 genotype. The DM/DX ratio in the
group of PMs with an activity score 0 was significantly
greater than in all of the other activity score groups, but
these ratios did not differ between IMs and the different
EM groups or within the EM groups (Supplementary
Table S1 and Supplementary Fig. S9, Supplemental
digital content 1, http://links.lww.com/FPC/B41). Despite
some discordance between individual genotypes and
phenotypes, the effects of the CYP2D6 genotype (Fig. 1)
and the CYP2D6 phenotype (Supplementary Fig. S10,
Supplemental digital content 1, http://links.lww.com/FPC/
B41) groups on MDMA and metabolite plasma–time
curves were very similar. Additional findings are pre-
sented in the Supplementary material, Supplemental
digital content 1, http://links.lww.com/FPC/B41.
Taken together, the present study found an increase in
MDMA exposure and more rapid increases in the cardi-
ostimulant and psychotropic effects of MDMA in indi-
viduals with poor CYP2D6 function. The mean Cmax
levels of MDMA in the seven CYP2D6 PMs in the
present study were only 1.15 times higher than in 111
EMs, and differences in the PK or subjective and blood
pressure responses to MDMA were only present in the
first hour after MDMA administration. Thus, inter-
individual differences in CYP2D6 function have a small
and transient effect on the plasma concentration of
MDMA and its pharmacodynamic effects. These find-
ings are consistent with the mechanism-based inhibition
of CYP2D6 by MDMA, turning all individuals into
functional CYP2D6 PMs within 1 h after MDMA
administration [4,5]. Consistent with our experimental
data, a physiologically based PK model estimated that the
absence of CYP2D6 function in PMs would increase
MDMA Cmax levels by only 36% [4]. Consistent with the
findings in genetically impaired CYP2D6 PMs in the
present study, the pharmacological inhibition of CYP2D6
function increased the Cmax and AUC values of MDMA
by 15–20 and 10–30%, respectively [6,7]. The mean
HMMA AUC6 in CYP2D6 PMs was four times lower
(24%) compared with EMs. This more pronounced effect
of the CYP2D6 genotype on HMMA concentrations
compared with MDMA concentrations could be clinically
relevant because metabolites that are formed by
CYP2D6, including HHMA and HMMA, have been
implicated in MDMA-induced neurotoxicity and hepa-
totoxicity [8], hyponatremia, and hyperthermia [9]. Low
CYP2D6 activity was associated with higher MDA levels.
Although CYP2D6 has been shown to be involved in the
N-demethylation of MDMA to MDA in-vitro [10], indi-
viduals with low CYP2D6 function appear to produce
more MDA because the main metabolic pathway of
CYP2D6-mediated MDMA-HMMA conversion is less
active, thus resulting in higher MDMA levels and com-
pensatory MDA formation. Altogether, statistically sig-
nificant but only moderate clinical effects of CYP2D6
genetics or pharmacological CYP2D6 inhibition on
MDMA disposition were found, effects that are attribu-
table to the self-inhibition of CYP2D6 and pheno-
conversion. CYP2D6 PMs were not overrepresented in
fatalities associated with ecstasy [11]. However, indivi-
duals may be at increased risk when more than one CYP
system is genetically impaired or pharmacologically
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inhibited. Severe or fatal MDMA toxicity and high
plasma exposure to MDMA were noted in cases of co-use
with ritonavir, which blocks not only CYP2D6 but also
CYP2B6 and CYP3A4. In fact, because CYP2D6 is
inhibited by MDMA itself in all individuals, poly-
morphisms in other CYPs (e.g. CYP1A2, CYP2C19, and
CYP2B6) and the pharmacological inhibition of CYP3A4
may actually be more clinically relevant than CYP2D6
genetics. Supporting this view, CYP1A2 function was
shown to increase after MDMA administration in another
study [12], which possibly compensated for the inhibition
of CYP2D6 function by MDMA. We have assessed
the effects of CYPA12, CYP2C19, and CYP2B6 poly-
morphisms on the PK of MDMA in this study and the
findings will be published separately. There were no
moderating effects of these polymorphisms on the effects
of CYP2D6.
The present study has limitations. We analyzed a pooled
sample of different studies and different doses and the
different CYP2D6 activity groups were not equally
represented across studies and dose groups. In addition,
there were only seven PMs and all were in the high-dose
group. However, an analysis of the high-dose group only
produced similar results as the analysis of the total sample.
In conclusion, the present study evaluated the CP2D6
pharmacogenetics of the PK of an important recreational
substance in a unique cohort that included a relatively
large number of individuals and a wide spectrum of CYP
functions, including CYP2D6 PMs. The study found
Fig. 2
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subjective effects, including any drug effects (b) and drug liking (c), increased more rapidly in CYP2D6 PMs compared with IMs and EMs. The data
are expressed as the mean ±SEM in seven PMs, 19 IMs, and 113 EMs. *P<0.05, **P<0.01, ***P<0.001, PMs compared with IMs or EMs at the
corresponding time. CYP2D6, cytochrome 2D6; EMs, extensive metabolizers; IM, intermediate metabolizers; MDMA, 3,4-methylene-
dioxymethamphetamine; PMs, poor metabolizers.
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only moderate increases in the plasma exposure to
MDMA and its active metabolite MDA and a more rapid
onset of associated blood pressure and psychotropic
effects in individuals with poor CYP2D6 function.
Although CYP2D6 PMs may be at increased risk for
MDMA toxicity, the self-inhibition of CYP2D6 reduces
the impact of the CYP2D6 genotype on MDMA PK.
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